This article reports recent research results that indicate that the use of popular high blood pressure drugs called ACE inhibitors may, during the first trimester of pregnancy, increase the rate of birth defects from 2.6 per 100 to 7.1 per 100. Although ACE inhibitors have been used for 25 years, the potential risk to human fetuses during the first third of pregnancy had not been explicitly studied.
The article would have been improved if it had included the fact that there may also be risks associated with not using ACE inhibitors for some women, such as those with congestive heart failure or diabetes.
Overall, this story was very well written and reported.
There was no cost comparison for ACE inhibitors and the other medications that might be used in the management of hypertension.
However, since the point of the story was to point out risks, not to promote further use, costs are less of an issue in this story.
There was no quanitification of possible benefits to the mother for using this drug during the first trimester of pregnancy. In some women the risks of taking the drug may be less than the risk of undertreatment.
The harms to the fetus of treating a mother with an ACE inhibitor during the first trimester of pregnancy are plainly mentioned. However the risks of NOT using ACE inhibitors in some women (congestive heart failure, diabetes) are not mentioned. This study was not done in a high risk group and the risks of undertreatment may be greater in some populations. So, for example, women with diabetes and renal dysfunction or those with congestive heart failure would have gotten an incomplete picture from the article.
The article referred to the original retrospective study and where it could be found (New England Journal of Medicine).
This article does not appear to disease monger. Although it does mention that these drugs ‘nearly tripled’ the rate of birth defects, it also attempted to lay out the numbers for what this really meant. But it botched the percentages. The story presents the rate of birth defects for women not taking blood pressure medication as 2.6%, though the data in the New England Journal of Medicine reported that there were 4 out of 202 infants born with birth defects in this group – which is 1.98%. The story mentioned that the rate of birth defects for those who had taken ACE inhibitors during the first trimester of pregnancy was 7.1%, though the journal article reported that there were 18 out of 209 in this group or a birth defect rate of 8.6%.
The article did not note that the data reported on the rate of birth defects after ACE inhibitor use during the first trimester only.
The sources of information appear to be the journal article, an author of the study and spokespersons from the FDA and its Center for Drug Evaluation and Research.
The article included a list of other medications that may be used to to lower blood pressure. However these suffer from the same lack of clinical testing of their safety for use in pregnant women. The story discussed the impact of pregnancy on blood pressure – lowering it for some women and raising it in others.
It is clear from the story that ACE inhibitors are a class of drugs available since the early 1980s; they are commonly prescribed.
It is clear from the story that ACE inhibitors have been used by pregnant women, and that “The number of women taking them early in pregnancy is unknown but probably is small, the study suggests.”
There is no evidence that this story relied on a news release.
Systematic, Criteria-Driven
Puleeeeease... this 'game changer' weight loss drug causes more nausea and vomiting than a placebo. Some game, some change. My friend Gary would spank you for using the eighth word medical reporters should never, ever use. @garyschwitzer @thackerpd
https://www.healthnewsreview.org/toolkit/just-journalists-writing-tips-case-studies/7-words-and-more-you-shouldnt-use-in-medical-news/ https://twitter.com/OttawaCitizen/status/1361426796126830597
A scary @statnews Op-Ed warns that govt attempts to rein in Pharma may cut off access to "life-changing" drugs.
It takes @garyschwitzer to let us know: the author spent 10 years as Pfizer's public-policy chief. https://twitter.com/garyschwitzer/status/1360325022578053123
.@TranspariMED criticizes STAT op-ed for not disclosing pharma funding of author’s institute - similar to criticism we’ve made of STAT op-eds in the past. @transparify @ThinkTankWatch @icer_review https://www.healthnewsreview.org/2021/02/transparency-watchdog-criticizes-stats-non-disclosure-on-pro-pharma-op-ed/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like